DWP
AQST icon

Daymark Wealth Partners’s Aquestive Therapeutics AQST Stock Holding History

Daymark Wealth Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Hold
38,278
– – ﹤0.01% 776
2026
Q1 		$159K Buy
38,278
+3,000
+9% +$12.2K 0.01% 717
2025
Q4 		$228K Buy
35,278
+10,000
+40% +$62.3K 0.01% 560
2025
Q3 		$141K Buy
25,278
+7,778
+44% +$33.6K ﹤0.01% 594
2025
Q2 		$57.9K Buy
+17,500
New +$50.2K ﹤0.01% 558

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Daymark Wealth Partners's AQST Position: Q2 2026 in Review

Daymark Wealth Partners held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 38,278 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #776.

Daymark Wealth Partners first reported a position in AQST in Q2 2025 and has held it in 5 quarters since. The position peaked at $228K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Daymark Wealth Partners held 38,278 shares of Aquestive Therapeutics worth $159K as of Q2 2026.
  • Daymark Wealth Partners left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Daymark Wealth Partners's portfolio in Q2 2026, its #776 holding.
  • Daymark Wealth Partners first reported a position in Aquestive Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Daymark Wealth Partners's Aquestive Therapeutics position peaked at $228K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.